Alexza Pharmaceuticals Inc - Strategic SWOT Analysis Review

Alexza Pharmaceuticals Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.

This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.

Scope

• Business description - A detailed description of the company’s operations and business divisions.
• Corporate strategy - The analyst’s summarization of the company’s business strategy.
• SWOT analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
• Company history - Progression of key events associated with the company.
• Major products and services - A list of major products, services and brands of the company.
• Key competitors - A list of key competitors to the company.
• Key employees - A list of the key executives of the company.
• Executive biographies - A brief summary of the executives’ employment history.
• Key operational heads - A list of personnel heading key departments/functions.
• Important locations and subsidiaries - A list of key locations and subsidiaries of the company, including contact details.

Highlights

Alexza Pharmaceuticals Inc (Alexza), a subsidiary of Ferrer Therapeutics Inc focuses on the research, development and commercialization of novel, proprietary products for the treatment of acute central nervous system diseases. The company develops its products based on its own proprietary technology, the Staccato system (a hand-held inhaler), which is the foundation for Adasuve (loxapine) and all other product candidates. The company’s lead product Adasuve (Staccato loxapine) is indicated for the treatment of agitation associated with schizophrenia or bipolar I disorder. The company’s pipeline products include Staccato apomorphine for the treatment of OFF episodes in patients with Parkinson’s disease, Staccato alprazolam intended for epileptic seizures; Staccato fentanyl for cancer breakthrough pain; and Staccato granisetron for cyclic vomiting syndrome. The company operates as a subsidiary of Ferrer Therapeutics Inc. Grupo Ferrer Internacional is headquartered in Mountain View, California, the US.

Reasons to Buy

• Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
• Identify potential customers and suppliers with this report’s analysis of the company’s business structure, operations, major products and services and business strategy.
• Understand and respond to your competitors’ business structure and strategies with the analyst’s detailed SWOT analysis. In this, the company’s core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
• Examine potential investment and acquisition targets with this report’s detailed insight into the company’s strategic, business and operational performance.

Note: Some sections may be missing if data is unavailable for the company.